Treatment of immunoglobulin A nephropathy:Current perspective and future prospects  

作　　者：Yusuf ZiyaŞener SeherŞener 

机构地区：[1]Department of Cardiology,Thoraxcentrum,Erasmus MC,Rotterdam 3015 GD,Netherlands [2]Department of Pediatric Rheumatology,Erasmus MC,Rotterdam 3015 GD,Netherlands

出　　处：《World Journal of Clinical Cases》2025年第19期5-10,共6页世界临床病例杂志(英文)

摘　　要：Immunoglobulin(Ig)A nephropathy is the most common type of primary glomerulonephritis globally.It typically manifests with microscopic hematuria and a spectrum of proteinuria,although rapidly progressive glomerulonephritis may occur in rare instances.Deposition of IgA in the mesangium seems to be the underlying disease mechanism.Despite current treatment,IgA nephropathy may progress into end-stage renal disease,indicating the necessity for the development of new therapeutic agents.Lifestyle modifications and anti-proteinuric treatment are recommended,and steroids have shown to be beneficial to high risk groups.Nevertheless,other conventional immunosuppressive agents,such as cyclophosphamide and mycophenolate mofetil,may be considered,despite the lack of sufficient evidence to support their efficacy.A considerable proportion of cases remain unresponsive to these treatments,underscoring the need for novel therapeutic approaches.There are several promising immunosuppressive drugs,such as B-cell lineage depleting agents or complement system inhibitors,that are currently undergoing clinical trials.These therapies may be considered for use in selected cases.

关 键 词：Immunoglobulin A nephropathy Telitacicept Complement inhibitors B-cell lineage depletion Anti-proteinuric treatment 

分 类 号：R69[医药卫生—泌尿科学]